Table 9Clinical evidence summary: People with non-arteritic anterior ischaemic optic neuropathy (NAION) vs control

OutcomesNo of Participants (studies) Follow upQuality of the evidence (GRADE)Relative effect (95% CI)Anticipated absolute effects
Risk with ControlRisk difference with Patients with non-arteritic anterior ischaemic optic neuropathy (95% CI)
Prevalence of OSA

40

(1 study)

⊕⊝⊝⊝

VERY LOW1,2

due to risk of bias, imprecision

RR 1.31

(0.9 to 1.89)

Moderate
650 per 1000

201 more per 1000

(from 65 fewer to 578 more)

1

Risk of bias was assessed using the QUIPS checklist. Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2

Default MID (0.5XSD) used to assess imprecision. Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs. GC considered the clinical importance of the effect estimate for each analysis on a case by case basis, taking into consideration the increment of the risk factor and the outcome under study.

From: When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome

Cover of When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome
When to suspect OSAHS, OHS and COPD–OSAHS overlap syndrome: Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Evidence review A.
NICE Guideline, No. 202.
National Guideline Centre (UK).
Copyright © NICE 2021.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.